MCID: PDT040
MIFTS: 30

Pediatric Hypertension

Categories: Rare diseases

Aliases & Classifications for Pediatric Hypertension

MalaCards integrated aliases for Pediatric Hypertension:

Name: Pediatric Hypertension 49

Classifications:



Summaries for Pediatric Hypertension

MalaCards based summary : Pediatric Hypertension is related to posterior urethral valves and anuria. An important gene associated with Pediatric Hypertension is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Peptide hormone metabolism and ACE Inhibitor Pathway, Pharmacodynamics. The drugs Ramipril and protease inhibitors have been mentioned in the context of this disorder. Affiliated tissues include kidney, testes and heart.

Related Diseases for Pediatric Hypertension

Diseases related to Pediatric Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 41)
# Related Disease Score Top Affiliating Genes
1 posterior urethral valves 10.0 ACE AGT
2 anuria 10.0 ACE AGT
3 aortic coarctation 10.0 ACE AGT
4 diastolic heart failure 10.0 ACE AGT
5 malignant hypertension 10.0 ACE AGT
6 fibromuscular dysplasia 10.0 ACE AGT
7 microvascular complications of diabetes 3 10.0 ACE AGT
8 oligohydramnios 10.0 ACE AGT
9 renal tubular dysgenesis 10.0 ACE AGT
10 ischemic optic neuropathy 9.9 ACE AGT
11 hypertensive heart disease 9.9 ACE AGT
12 interstitial nephritis 9.9 ACE AGT
13 mitral valve disease 9.9 ACE AGT
14 renal dysplasia 9.9 ACE AGT
15 end stage renal failure 9.9 ACE AGT
16 meningococcal infection 9.8 ADD1 AGT
17 aortic valve disease 2 9.8 ACE AGT
18 otosclerosis 9.8 ACE AGT
19 arteries, anomalies of 9.8 ACE AGT
20 chronic kidney failure 9.7 ACE AGT
21 body mass index quantitative trait locus 11 9.7
22 body mass index quantitative trait locus 9 9.7
23 body mass index quantitative trait locus 8 9.7
24 body mass index quantitative trait locus 4 9.7
25 body mass index quantitative trait locus 10 9.7
26 body mass index quantitative trait locus 7 9.7
27 body mass index quantitative trait locus 12 9.7
28 body mass index quantitative trait locus 14 9.7
29 body mass index quantitative trait locus 18 9.7
30 atrial fibrillation 9.7 ACE AGT
31 diabetes mellitus 9.5 ACE AGT
32 pyelonephritis 9.4
33 kidney disease 9.4
34 aneurysm 9.4
35 aging 9.4
36 body mass index quantitative trait locus 1 9.4
37 burns 9.4
38 chronic pyelonephritis 9.4
39 autosomal dominant polycystic kidney disease 9.4 ACE ADD1 AGT
40 hypertension, essential 9.4 ACE ADD1 AGT
41 myocardial infarction 9.3 ACE ADD1 AGT

Graphical network of the top 20 diseases related to Pediatric Hypertension:



Diseases related to Pediatric Hypertension

Symptoms & Phenotypes for Pediatric Hypertension

Drugs & Therapeutics for Pediatric Hypertension

Drugs for Pediatric Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 26)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ramipril Approved Phase 4 87333-19-5 5362129
2
protease inhibitors Phase 4,Phase 3
3 HIV Protease Inhibitors Phase 4,Phase 3
4 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 3
5 Antihypertensive Agents Phase 4,Phase 3,Phase 2
6
Enalapril Approved, Vet_approved Phase 3 75847-73-3 40466924 5362032
7
Enalaprilat Approved Phase 3 76420-72-9 6917719
8
Valsartan Approved, Investigational Phase 3 137862-53-4 60846
9
Metoprolol Approved, Investigational Phase 3 51384-51-1, 37350-58-6 4171
10
Angiotensin II Approved, Investigational Phase 3,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
11
Losartan Approved Phase 3,Phase 2 114798-26-4 3961
12
Candesartan Experimental Phase 3 139481-59-7 2541
13
Candesartan cilexetil Phase 3 145040-37-5 2540
14 Adrenergic Agents Phase 3
15 Adrenergic Antagonists Phase 3
16 Adrenergic beta-1 Receptor Antagonists Phase 3
17 Adrenergic beta-Antagonists Phase 3
18 Sympatholytics Phase 3
19 Neurotransmitter Agents Phase 3
20 Angiotensin II Type 1 Receptor Blockers Phase 3,Phase 2
21 Angiotensin Receptor Antagonists Phase 3,Phase 2
22 Angiotensinogen Phase 3,Phase 2
23 Peripheral Nervous System Agents Phase 3
24 Anti-Arrhythmia Agents Phase 3,Phase 2
25 Pharmaceutical Solutions Phase 3
26 Autonomic Agents Phase 3

Interventional clinical trials:

(show all 19)

# Name Status NCT ID Phase Drugs
1 Treatment of Pediatric Hypertension With Altace Trial Completed NCT00044265 Phase 4 ramipril
2 A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have Hypertension Completed NCT00171028 Phase 3 valsartan
3 A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension Completed NCT02451150 Phase 3 Azilsartan
4 Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age Completed NCT00244634 Phase 3 candsartan cilexetil
5 Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD Completed NCT01617681 Phase 3 VAL489;VAL489 matching placebo
6 Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects Completed NCT00255528 Phase 3 metoprolol succinate
7 307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects Completed NCT00255502 Phase 3 metoprolol succinate
8 Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age Completed NCT00244621 Phase 3 candesartan cilexetil (Atacand);candesartan cilexetil (Atacand);candesartan cilexetil (Atacand)
9 Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age Completed NCT00244595 Phase 3 candsartan cilexetil
10 Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age Completed NCT01150357 Phase 3 Aliskiren (6.25/12.5/25 mg);Aliskiren (37.5/75/150 mg);Aliskiren (150/300/600 mg)
11 A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age Completed NCT00171041 Phase 3 valsartan
12 An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age Completed NCT01151410 Phase 3 Aliskiren;Enalapril
13 A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension Recruiting NCT02791438 Phase 3 TAK-536 2.5 mg;TAK-536 5 mg
14 An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension Recruiting NCT02235909 Phase 3 Azilsartan Medoxomil;Losartan;Placebo for Azilsartan Medoxomil;Placebo for Losartan
15 Preventing Sickle Cell Kidney Disease Recruiting NCT02373241 Phase 2 Losartan;Losartan
16 A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension Withdrawn NCT00528827 Phase 2 Cardene® I.V.
17 Improving Outcomes for Hypertensive Children Completed NCT01485783
18 Ewha Birth and Growth Study (Birth Cohort) Active, not recruiting NCT03351595
19 Pediatric Hypertension Registry (PHREG) Enrolling by invitation NCT03305562

Search NIH Clinical Center for Pediatric Hypertension

Genetic Tests for Pediatric Hypertension

Anatomical Context for Pediatric Hypertension

MalaCards organs/tissues related to Pediatric Hypertension:

38
Kidney, Testes, Heart

Publications for Pediatric Hypertension

Articles related to Pediatric Hypertension:

(show top 50) (show all 122)
# Title Authors Year
1
Pediatric Hypertension: Provider Perspectives. ( 28620629 )
2017
2
Adverse Outcomes in Pediatric Hypertension. ( 29084875 )
2017
3
Hypertension Canada's 2017 Guidelines for the Diagnosis,A Assessment, Prevention, and Treatment ofA Pediatric Hypertension. ( 28449829 )
2017
4
Can Pediatric Hypertension Criteria Be Simplified? A Prediction Analysis of Subclinical Cardiovascular Outcomes From the Bogalusa Heart Study. ( 28223474 )
2017
5
Changes in the 2017 Pediatric Hypertension Clinical Guidelines. ( 29087430 )
2017
6
Left Ventricular Hypertrophy in Pediatric Hypertension: A Mini Review. ( 28553631 )
2017
7
Primary Pediatric Hypertension: Current Understanding and Emerging Concepts. ( 28780627 )
2017
8
Definition of pediatric hypertension: are blood pressure measurements on three separate occasions necessary? ( 28077857 )
2017
9
Commentary: Left Ventricular Hypertrophy in Pediatric Hypertension: A Mini Review. ( 29164085 )
2017
10
Assessment of Left Ventricular Mass and Hypertrophy by Cardiovascular Magnetic Resonance Imaging in Pediatric Hypertension. ( 26988578 )
2016
11
SY 13-2 LONG-TERM CARDIOVASCULAR RISK REDUCTION IN PEDIATRIC HYPERTENSION. ( 27643124 )
2016
12
OS 26-05 HOW TO ACCURATELY DEFINE PEDIATRIC HYPERTENSION: A SYSTEMATIC REVIEW. ( 27754136 )
2016
13
Diagnosis and Medication Treatment of Pediatric Hypertension: A Retrospective Cohort Study. ( 27940711 )
2016
14
ED 08-3 APPLICATION OF ABP MONITORING IN THE MANAGEMENT OF PEDIATRIC HYPERTENSION. ( 27754179 )
2016
15
Pharmacologic Management of Pediatric Hypertension. ( 26597490 )
2016
16
Pediatric Hypertension: Are Pediatricians Following Guidelines? ( 27659546 )
2016
17
In-Clinic Blood Pressure Prediction of Normal Ambulatory Blood Pressure Monitoring in Pediatric Hypertension Referrals. ( 27205889 )
2016
18
Vascular Aging: Lessons From Pediatric Hypertension. ( 27040097 )
2016
19
Re: Pediatric Hypertension and Cardiac Hypertrophy. ( 26739585 )
2016
20
OS 26-05 HOW TO ACCURATELY DEFINE PEDIATRIC HYPERTENSION: A SYSTEMATIC REVIEW. ( 27643063 )
2016
21
ED 08-3 APPLICATION OF ABP MONITORING IN THE MANAGEMENT OF PEDIATRIC HYPERTENSION. ( 27643136 )
2016
22
SY 13-2 LONG-TERM CARDIOVASCULAR RISK REDUCTION IN PEDIATRIC HYPERTENSION. ( 27754169 )
2016
23
Pharmacologic Treatment of Pediatric Hypertension. ( 27048353 )
2016
24
Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, and Assessment of Risk of Pediatric Hypertension. ( 27118292 )
2016
25
Diagnosis of primary versus secondary pediatric hypertension. ( 25594296 )
2015
26
Pediatric hypertension in the Eastern Province of Saudi Arabia. ( 25987114 )
2015
27
Cardiovascular target organ damage could have been detected in sustained pediatric hypertension. ( 26024395 )
2015
28
Pediatric hypertension: a pharmacological review. ( 25898872 )
2015
29
Racial Differences of Pediatric Hypertension in Relation to Birth Weight and Body Size in the United States. ( 26176843 )
2015
30
Recent clinical and translational advances in pediatric hypertension. ( 25712720 )
2015
31
Abnormalities of vascular structure and function in pediatric hypertension. ( 26275663 )
2015
32
Impaired cardiac autonomic nervous system function is associated with pediatric hypertension independent of adiposity. ( 26389821 )
2015
33
Pediatric hypertension: a pharmacological review. ( 25898873 )
2015
34
Hypertension editors' picks: pediatric hypertension. ( 25855321 )
2015
35
Is Daytime Systolic Load an Important Risk Factor for Target Organ Damage in Pediatric Hypertension? ( 26140344 )
2015
36
The relationship between currently recommended ambulatory systolic blood pressure measures and left ventricular mass index in pediatric hypertension. ( 25794952 )
2015
37
Pediatric hypertension: a growing problem. ( 25634711 )
2015
38
Essential pediatric hypertension: defining the educational needs of primary care pediatricians. ( 25063988 )
2014
39
Pediatric hypertension: often missed and mismanaged. ( 24701598 )
2014
40
Pediatric Hypertension Specialists' Perspectives About Adolescent Hypertension Management: Implications for Primary Care Providers. ( 25398627 )
2014
41
Gene polymorphisms of adducin GLY460TRP, ACE I/D, AND AGT M235T in pediatric hypertension patients. ( 25262176 )
2014
42
Pediatric hypertension: An update on a burning problem. ( 24944755 )
2014
43
Clinical predictors and impact of ambulatory blood pressure monitoring in pediatric hypertension referrals. ( 25065681 )
2014
44
Response to "U.S. Preventive Services Task Force recommendation and pediatric hypertension screening: dereliction of duty or call to arms?". ( 24720549 )
2014
45
Autonomic nervous system dysregulation in pediatric hypertension. ( 24633841 )
2014
46
U.S. Preventive Services Task Force recommendation and pediatric hypertension screening: dereliction of duty or call to arms? ( 24720583 )
2014
47
Bioequivalence of enalapril oral solution for treatment of pediatric hypertension and enalapril tablets. ( 27129124 )
2014
48
Serum urate: a biomarker or treatment target in pediatric hypertension? ( 23736817 )
2013
49
Concordance of Measures of Left-Ventricular Hypertrophy in Pediatric Hypertension. ( 24253610 )
2013
50
Executive Function and Cerebrovascular Reactivity in Pediatric Hypertension. ( 23877480 )
2013

Variations for Pediatric Hypertension

Expression for Pediatric Hypertension

Search GEO for disease gene expression data for Pediatric Hypertension.

Pathways for Pediatric Hypertension

GO Terms for Pediatric Hypertension

Biological processes related to Pediatric Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kidney development GO:0001822 9.43 ACE AGT
2 regulation of blood pressure GO:0008217 9.4 ACE AGT
3 positive regulation of protein tyrosine kinase activity GO:0061098 9.37 ACE AGT
4 blood vessel remodeling GO:0001974 9.32 ACE AGT
5 regulation of vasoconstriction GO:0019229 9.26 ACE AGT
6 angiotensin maturation GO:0002003 9.16 ACE AGT
7 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 8.96 ACE AGT
8 regulation of renal output by angiotensin GO:0002019 8.62 ACE AGT

Sources for Pediatric Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....